Credit: Vasyl/Adobe Stock

Biotech pharmaceutical companies may be poised for a big year in 2024. The U.S. Food and Drug Administration approved nearly 50% more novel drugs last year than in 2022, raising optimism among industry analysts and investors.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Employee Participation
Employee-Paid
Employer-Paid